FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
Acura Pharmaceuticals’ stock fell 11% May 28 after the company revealed that FDA advised an abuse liability study for its hydrocodone/acetaminophen product would not support an abuse liability claim.
You may also be interested in...
Egalet Ramps Up Commercial Ahead Of Abuse-Deterrent Pain Drug Filing
The specialty pharma has relaunched two drugs for pain – Sprix and Oxaydo – supported by a 50-person sales team, laying the groundwork to eventually bring to market an abuse-deterrent, extended-release morphine product.
Abuse-Deterrent Opioid Claims Need Studies, Studies And More Studies
FDA’s review of Purdue’s Targiniq ER, one of only two opioids with approved abuse-deterrent claims, shows that the agency’s skepticism about the state of the technology to deter opioid abuse can be overcome – by an exhaustive set of comparisons in clinical, in vitro and PK studies.
In Brief: Amarin Perseveres With Vascepa Outcomes Trial, Cochrane Review Reignites Lucentis Cost Debate
Plus Acura’s own appeal on abuse-deterrent opioid, TG Therapeutics gets FDA buy-in for ublituximab accelerated approval plan, and Amgen presents more analysis supporting heart failure drug ivabradine after Servier’s failed outcomes trial.